Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Effectiveness of QLS4131 Injection in Patients With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 23 Jul 2024
At a glance
- Drugs QLS-4131 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 23 Jul 2024 New trial record